Protara Therapeutics Reports Positive Interim Phase 2 Data for TARA-002 in Bladder Cancer
Summary
Protara Therapeutics announced updated positive interim results from its Phase 2 ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile in both BCG-Unresponsive and BCG-Naïve patients.
Key Events
-
Positive Phase 2 Interim Data
TARA-002 demonstrated a 68.2% complete response rate at six months in BCG-Unresponsive NMIBC patients and 66.7% in BCG-Naïve patients.
-
Durable Responses Observed
Among responders, 71.1% (BCG-Unresponsive) and 73.1% (BCG-Naïve) maintained a complete response for six months.
-
Favorable Safety Profile
The trial reported no Grade 3 or greater treatment-related adverse events (TRAEs) and no related serious adverse events.
-
Advancing to Registrational Trials
The company plans to complete enrollment for the BCG-Unresponsive cohort and initiate the ADVANCED-3 registrational trial for BCG-Naïve patients in the second half of 2026.
Analysis
The updated interim data from the ADVANCED-2 trial demonstrates TARA-002's potential as a significant treatment option for high-risk non-muscle invasive bladder cancer. The reported complete response rates of 68.2% at six months in BCG-Unresponsive patients and 66.7% at six months in BCG-Naïve patients, coupled with encouraging durability and a clean safety profile (no Grade 3+ TRAEs), are highly encouraging. These results support the company's plans to complete enrollment for the BCG-Unresponsive cohort and initiate a registrational trial for BCG-Naïve patients in the second half of 2026, marking a critical step forward in the drug's development.
At the time of this filing, TARA was trading at $6.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $383.6M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.